Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CURATE.AI Dose Optimisation of Nivolumab and Pembrolizumab in Solid Tumours
NCT05175235Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Aug 2021
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, pembrolizumab in solid tumor, non-small cell lung cancer (NSCLC), gastric cancer (GC), hepatocellular carcinoma (HCC), nasopharyngeal carcinoma (NPC), sponsored by National University Hospital. Status: unknown.
02
Drugs
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)gastric cancer (GC)hepatocellular carcinoma (HCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05175235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175235.